Navigation Links
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
Date:3/16/2008

otherapy were deemed eligible for consolidation treatment six to ten weeks after the sixth cycle with one course of Zevalin. Primary endpoints were complete response and hematological toxic effects and secondary endpoints were overall survival and progression-free survival.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell NHL, including patients with Rituximab-refractory NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit http://www.zevalin.com for more information.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
2. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
3. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
4. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
5. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
6. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
7. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
8. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
9. First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
10. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
11. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- More than half of women diagnosed with early ... still have excellent outcomes. To educate women, Agendia, Inc. ... sources of online consumer information about breast cancer genomic ... recently diagnosed women with information sources, to help them ... "We anticipate these innovative social media campaigns will encourage ...
(Date:5/23/2013)... , May 23, 2013  Texas, premier physician associations ... doctors the survival tools they need to provide demonstrably ... today,s health care marketplace. "I am confident ... local practices," said Stephen L. Brotherton ... " Texas doctors are determined to ...
(Date:5/23/2013)...  Ameritox, the nation,s leader in pain medication ... to become part of its Urine Drug Monitoring ... and improve the clinical outcomes for injured workers. ... manager in the workers, compensation industry, has used ... management strategy for several years. By establishing a ...
Breaking Medicine Technology:Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 2Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 3
... and SAN DIEGO, Nov. 12 Tobira Therapeutics, ... and product discovery for the treatment of life-threatening ... and results from two double-blind, placebo-controlled studies of ... studies, a single-ascending dose (SAD) study and the ...
... , BOTHELL, Wash., Nov. 11 ... ), a global leader in automated external defibrillator ( ... appointed Peter Kingma as senior vice president, effective immediately. ... Marver, president and chief executive officer, and oversees the ...
Cached Medicine Technology:Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference 2Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 2Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 3Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 4Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 5
(Date:5/24/2013)... The point-of-care (POC) diagnostics market ... the central laboratory, by other healthcare professionals, patient ... by consumers. This includes products that test blood ... and cardiovascular disease and cancer, as well as ... surgical and emergency departments. , Critical analysis and ...
(Date:5/24/2013)... is available in German . ... "alpha-synuclein" aggregates and accumulates within neurons. Specific areas of ... and advances. The mechanism underlying this pathological progression is ... protein (or abnormal forms of it) along nerve projections ... the German Center for Neurodegenerative Diseases (DZNE) in Bonn ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 On May ... seventh commencement ceremony of American University of Antigua ... in Lincoln Center. , This was the largest graduating ... ceremonies Dick Woodward, AUA’s Senior Vice President for Enrollment ... and Dr. Reza Sanii, Associate Dean of Students and ...
(Date:5/24/2013)... (HealthDay News) -- Nearly three out of four ... and diarrhea, but these issues don,t significantly affect ... Researchers from Loyola University Medical Center in ... due to physiological and hormonal changes that occur ... pregnancy also can play a role. The study ...
(Date:5/24/2013)... 24, 2013 According to the new ... Global Forecasts (2011 - 2016)” published by MarketsandMarkets, global ... million by the end of year 2010 and is ... a CAGR of 17.9% from 2011 to 2016. , ... , 44 Figures , 370 ...
Breaking Medicine News(10 mins):Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 3Health News:Proteins in migration 2Health News:Proteins in migration 3Health News:Proteins in migration 4Health News:AUA Celebrates Seventh Annual Commencement Ceremony 2Health News:Bowel Issues Affect 3 Out of 4 Pregnant Women 2Health News:Micro Irrigation System Market to Reach $3414.7 Million by 2016 at a CAGR of 17.9% - New Report by MarketsandMarkets 2Health News:Micro Irrigation System Market to Reach $3414.7 Million by 2016 at a CAGR of 17.9% - New Report by MarketsandMarkets 3
... to vaccinate put others at risk, researcher says , MONDAY, ... trip to Switzerland in 2008 ended up as a public ... was intentionally unvaccinated against measles, was exposed to the virus ... Diego, he unknowingly exposed a total of 839 people, and ...
... , March 22, 2010 Dr. Rita Colwell ,distinguished Professor from the University of Maryland ... the 2010 Stockholm Water Prize Laureate. Dr. Colwell,s pioneering,research on the prevention of waterborne infectious diseases has helped,protect the ... ... , , ...
... , at the newly opened Rise Club , 6801 W. Hollywood Blvd., Hollywood, CA. , ... , , ... ... "We,ve walked for it, we,ve run ...
... children in schools across the country, and employees of workplaces nationwide will wear purple to support epilepsy awareness on March 26 . Thousands of Americans will also join the ... ... ... ...
... Representatives showed they have heard the voice of America,s families by passing the Patient Protection and Affordable Care Act and sending it ... the nation,s leading Hispanic health advocacy group. , ... ... ...
... ... Online Communications Program , ... (PRWEB) March 22, 2010 -- The Society for New Communications Research ( http://sncr.org ... latest developments in media and communications, today announced that it has received a $200,000 ...
Cached Medicine News:Health News:Measles Outbreak Triggered by Unvaccinated Child 2Health News:Measles Outbreak Triggered by Unvaccinated Child 3Health News:American Public Health Champion Receives 2010 Stockholm Water Prize 2Health News:American Public Health Champion Receives 2010 Stockholm Water Prize 3Health News:MAYO Communications Retained by MAMMOJAM 2010 Dr. Susan Love Research Foundation Event 2Health News:MAYO Communications Retained by MAMMOJAM 2010 Dr. Susan Love Research Foundation Event 3Health News:Purple Day March 26th: The United States Goes Purple in Support of Epilepsy Awareness 2Health News:Purple Day March 26th: The United States Goes Purple in Support of Epilepsy Awareness 3Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Reconciliation Bill 2Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Reconciliation Bill 3Health News:Society for New Communications Research Receives Grant to Help Raise Awareness and Reduce Racial and Ethnic Health Disparities 2Health News:Society for New Communications Research Receives Grant to Help Raise Awareness and Reduce Racial and Ethnic Health Disparities 3Health News:Society for New Communications Research Receives Grant to Help Raise Awareness and Reduce Racial and Ethnic Health Disparities 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: